DISCOVERY: Georgia State Honors College Undergraduate
Research Journal
Volume 1 DISCOVERY - Georgia State University
Honors College Undergraduate Research
Journal

Article 12

2012

Evaluation of the Seca Inhibitors as Novel Anti-Microbial Agents
Christina Cerovsky
Georgia State University

Jinshan Jin
Georgia State University

Hsiuchin Yang
Georgia State University

Binghe Wang
Georgia State University

Phang C. Tai
Georgia State University

Follow this and additional works at: https://scholarworks.gsu.edu/discovery
Part of the Medicine and Health Sciences Commons

Recommended Citation
Cerovsky, Christina; Jin, Jinshan; Yang, Hsiuchin; Wang, Binghe; and Tai, Phang C. (2012) "Evaluation of
the Seca Inhibitors as Novel Anti-Microbial Agents," DISCOVERY: Georgia State Honors College
Undergraduate Research Journal: Vol. 1, Article 12.
DOI: https://doi.org/10.31922/disc1.12
Available at: https://scholarworks.gsu.edu/discovery/vol1/iss1/12

This Article is brought to you for free and open access by ScholarWorks @ Georgia State University. It has been
accepted for inclusion in DISCOVERY: Georgia State Honors College Undergraduate Research Journal by an
authorized editor of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.

Due to the misuse of conventional antibiotics and
natural selection of the infectious bacterial population, drug
resistance has emerged. Thus, there is an increasing need for
novel, more effective antibiotic compounds that are successful in
treating bacterial infections currently resistant to available
therapies. SecA is an indispensable ATPase of the protein
translocation machinery present in all bacteria. It is responsible
for the secretion of many essential proteins, some toxins and
virulence factors, and essential for bacterial survival. SecA has no
counterpart in mammalian cells, thus providing an ideal target for
developing antimicrobial agents. SCA-13 (HO) is a pyrimidine
analog and was derived from
virtual screening, exerts the ability
to inhibit SecA translocation ATPase
activity with an IC50 of 75 µM.
Moreover, HO showed promising
bacteriostatic activities against a
vacomycin resistance strain of S.
aureus Mu50 and B. anthracis
Sterne. No significant difference in
antimicrobial activity of HO was
observed among efflux pump
Strains of S. aureus, suggesting that compound HO is not a
substrate of NorA or MepA efflux pumps. Resistant mutants of E.
coli NR698 selected from HO will be characterized to gain a better
understanding the mechanisms of resistance and subsequently find
the drug target.

The compound HO was tested in samples with the overexpression
(++) and deletion (-) of MepA and NorA efflux pumps.

IC50

As HO increases, a new band is seen in the tryptic digest, indicating
that the drug alters the SecA conformation. This could indicate that
SecA is the target for HO.

http://biology.gsu.edu/5732.html
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One of the methods of resistance is for the compound/ treatment
to be pumped out of the cell via an efflux pump. We examined the
effect of changes in the MepA and NorA efflux pumps on the HO
compound. MepA and NorA efflux pumps are illustrated above.
NorA is a member of the SMR family of efflux pumps.
100
WT (83254)

EMS Mutagenesis: E. coli strain NR698 was grown to mid-log phase (O.D. 600=0.5) and treated with 0.5% or
1% EMS for 1 h at 37ºC. Cells were washed with 5% sodium thiosulfate to inactivate the EMS. 104 to 106 cells
were transferred to fresh LB agar plates containing various concentrations of compound HO and incubated at
37ºC until colonies formed. The resistant colonies were further confirmed by numerous passages on selection
plates
and
untreated
NR698
cells
were
used
as
a
control.
Inhibition Assay: Efflux strains of S. aureus were grown on LB plates and inoculated in 2 mL of LB. Different
strains included K1758 (NorA-), K2361 (NorA++), K2908 (MepA-), WT (83254), and K2068 (MepA++). The LB
medium for the appropriate sample was treated with the corresponding antibiotic. The treatment for K2361
(NorA++) was Cm (2 µl/2 mL) and the Ery chemical treatment (8 µl/2 mL) was for the K1758 (NorA-) and K2908
(MepA-). The OD was measured and the mid-log samples were diluted to 0.05. The 5 different strains were then
tested using different concentrations of antibiotic treatments. They were left in the incubator for 14 hrs at 37°C
at 100 rpm.
SecA translocation ATPase assay: Translocation ATPase assay was carried out at 40oC for 30 mins using
Malachite Green colorimetric method. Urea-treated SecA-depleted BA-13 membranes and preprotein pOmpA
were used in the reaction.
DARTS for purified protein binding: Ten- µg SecA protein was incubated at 37oC for 10 mins after the addition
of the proper inhibitor. The inhibitors include 0 mM, 2 mM, and 10 mM of HO, HA1, and NR698-17. This was
followed by digestion with 2 µl trypsin on ice for 10 mins. Adding sample buffer and boiling for 20 mins stopped
the digestion. SDS-PAGE (12%) was used to investigate the trypsin digestion pattern.
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The compound HO was tested in samples with the
overexpression (++) and deletion (-) of MepA and NorA efflux
pumps as shown by the IC50 values.

HO is a potent inhibitor for SecA that seems to be unaffected by
an efflux pump. This particular compound, when bound to SecA
alters the trypsin digest which indicates that HO changes the
confirmation of SecA.
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